Evidence map›Paper›PMID 7862671›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1995

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.

E Y Krynetski, J D Schuetz, A J Galpin, C H Pui, M V Relling, W E Evans

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 307 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Exploring Water-Soluble South AfricanCurrent issues in molecular biology · 2024
    Article
  11. Article
  12. Population-Specific Distribution ofTherapeutics and clinical risk management · 2023
    Article
  13. Article
  14. Review
  15. Ontogeny of Pediatric Pharmacogenetics: Celebrating the Past and Vision for the Future.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
    Article
  16. Article
  17. Article
  18. Role of Genetic Variations in the Hepatic Handling of Drugs.International journal of molecular sciences · 2020 · on this map
    Review
  19. Massively parallel variant characterization identifiesProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

E Y KrynetskiPharmaceutical Department, St. Jude Children's Research Hospital, Memphis, TN 38105.
J D Schuetz
A J Galpin
C H Pui
M V Relling
W E Evans
St. Jude Children's Research Hospital · USTriangle · USUniversity of Tennessee at Knoxville · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)R37CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1987 to 2014
$9.7M
TREATMENT OF RELAPSEP01CA020180 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOOK, A THOMAS · 1985 to 1997
–
NCI NIH HHS CA20180NCI NIH HHS CA21765NCI NIH HHS R37 CA36401
6 · The paper itself

Abstract

Thiopurine S-methyltransferase (TPMT; S-adenosyl-L-methionine:thiopurine S-methyltransferase, EC 2.1.1.67) activity exhibits genetic polymorphism, with approximately 0.33% of Caucasians and African-Americans inheriting TPMT deficiency as an autosomal recessive trait. To determine the molecular genetic basis for this polymorphism, we cloned the TPMT cDNA from a TPMT-deficient patient who had developed severe hematopoietic toxicity during mercaptopurine therapy. Northern blot analysis of RNA isolated from leukocytes of the deficient patient demonstrated the presence of TPMT mRNAs of comparable size to that in subjects with high TPMT activity. Sequencing of the mutant TPMT cDNA revealed a single point mutation (G238-->C), leading to an amino acid substitution at codon 80 (Ala80-->Pro). When assessed in a yeast heterologous expression system, this mutation led to a 100-fold reduction in TPMT catalytic activity relative to the wild-type cDNA, despite a comparable level of mRNA expression. A mutation-specific PCR amplification method was developed and used to detect the G238-->C mutation in genomic DNA of the propositus and her mother. This inactivating mutation in the human TPMT gene provides insights into the genetic basis for this inherited polymorphism in drug metabolism.

Indexed as

Point MutationAllelesBase SequenceCatalysisChildCloning, MolecularDNA, ComplementaryFemaleGenotypeHumansMethyltransferasesMolecular Sequence DataPolymorphism, Restriction Fragment LengthRNA, MessengerSaccharomyces cerevisiaeTranscription, GeneticDNA, ComplementaryMethyltransferasesRNA, Messengerthiopurine methyltransferase

Identifiers

PMID7862671
PMCPMC42614
OpenAlexW2084271415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.